Drug Type Universal CAR-T |
Synonyms Anti-EGFRvIII CAR-T cell therapy (Suzhou Maximum Biotech), AntiEGFRvIII CAR T cell therapy Suzhou Maximum Biotech, EGFRvIII CART cell therapy Suzhou Maximum Biotech + [2] |
Target |
Mechanism EGFRvIII antagonists(Epidermal growth factor receptor variant III antagonists), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioma of Brain, Familial | Preclinical | CN | 30 Jan 2022 |